Search hospitals
>
Illinois
>
Niles
Illinois Cancer Specialists-Niles
Claim this profile
Niles, Illinois 60714
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lymphoma
Conducts research for Pancreatic Cancer
167 reported clinical trials
3 medical researchers
Summary
Illinois Cancer Specialists-Niles is a medical facility located in Niles, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lymphoma, Pancreatic Cancer and other specialties. Illinois Cancer Specialists-Niles is involved with conducting 167 clinical trials across 174 conditions. There are 3 research doctors associated with this hospital, such as Leonard Klein, Urszula Sobol, MD, and Sonia Christian, MD.
Area of expertise
Lung Cancer
Illinois Cancer Specialists-Niles has run 35 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
Illinois Cancer Specialists-Niles has run 24 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Leonard Klein
Illinois Cancer Specialists
5 years of reported clinical research
Urszula Sobol, MD
Illinois Cancer Specialists
6 years of reported clinical research
Sonia Christian, MD
Illinois Cancer Specialists / Advocate Lutheran General Hospital
6 years of reported clinical research
Clinical Trials running at Illinois Cancer Specialists-Niles
Lung Cancer
Non-Small Cell Lung Cancer
Follicular Lymphoma
Multiple Myeloma
Cancer
Small Cell Lung Cancer
Non-Hodgkin's Lymphoma
Tumors
Pancreatic Cancer
Ovarian Cancer
Sotorasib Combo vs Pembrolizumab Combo
for Advanced Lung Cancer
This trial is testing two different drug combinations with chemotherapy to see which helps cancer patients live longer without their disease getting worse. One combination includes sotorasib, which targets cancer mutations, and the other includes pembrolizumab, which helps the immune system fight cancer. Pembrolizumab has been shown to improve overall survival in various cancers when combined with chemotherapy.
Recruiting
2 awards
Phase 3
3 criteria
Amivantamab Combinations
for Non-Small Cell Lung Cancer
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Recruiting
1 award
Phase 2
3 criteria
Observational Study
for Lung Cancer
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Recruiting
1 award
N/A
5 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Illinois Cancer Specialists-Niles?
Illinois Cancer Specialists-Niles is a medical facility located in Niles, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lymphoma, Pancreatic Cancer and other specialties. Illinois Cancer Specialists-Niles is involved with conducting 167 clinical trials across 174 conditions. There are 3 research doctors associated with this hospital, such as Leonard Klein, Urszula Sobol, MD, and Sonia Christian, MD.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.